semaglutide alzheimer trial Novo Nordisk says semaglutide, the drug used in Wegovy and Ozempic, does not slow Alzheimer's progression, despite early real-world signals that prompted two major Evoke trials involving more than 3,800 participants aged Semaglutide may reduce Alzheimer's risk

Key takeaways: Glucagon-like peptide-1 (GLP-1) medications such as Ozempic (semaglutide) and Mounjaro (tirzepatide) are commonly covered by insurance when prescribed for Type 2 diabetes, cardiovascular risk reduction, or other FDA-approved indications

Relationship between deterioration of glycated hemoglobin-lowering effects in dipeptidyl peptidase-4 inhibitor monotherapy and dietary habits: retrospective analysis of Japanese individuals with type 2 diabetes

Omada Health has more than one million members who have enrolled in its programs and more than 1,900 employer, health plan and health system partners

Gut Microbiome Dysbiosis, Inflammation, and Systemic Risk Subsequently, gut microbiome dysbiosis has been associated with metabolic dysfunction, poor mental health, chronic disease, cardiovascular disease (CVD), reduced longevity, neurodegeneration, and inflammation

When skin is inflamed, its hard to see benefits from anything